中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.014 seconds)

    METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES
    1.
    发明申请
    METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES 审中-公开
    与血液恶性肿瘤相关的方法和组成

    公开(公告)号：WO2010124283A3

    公开(公告)日：2011-03-03

    申请号：PCT/US2010032416

    申请日：2010-04-26

    Applicant: JACKSON LAB ,  LI SHAOGUANG

    Inventor： LI SHAOGUANG

    IPC: A61K31/38 ,  A61K31/415 ,  A61K31/65 ,  A61P19/08 ,  A61P35/00

    CPC classification number: A61K31/38 ,  A61K31/415 ,  A61K31/65 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5- lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the present invention. In some embodiments, two or more 5-LO inhibitors are administered to a subject to treat a myeloproliferative disorder. In further embodiments, at least one 5-LO inhibitor and at least one additional therapeutic agent are administered to a subject to treat a myeloproliferative disorder. Methods of inhibiting leukemia stem cells are provided according to embodiments of the present invention which include contacting leukemia stem cells with an effective amount of an arachidonate 5-lipoxygenase inhibitor.

    Abstract translation: 根据本发明的实施方案提供治疗患有或具有骨髓增生性疾病风险的受试者的方法，其包括向受试者施用治疗有效量的花生四烯酸5-脂氧合酶（5-LO）抑制剂。 根据本发明的实施方案施用治疗剂的组合。 在一些实施方案中，将两种或更多种5-LO抑制剂施用于受试者以治疗骨髓增生性疾病。 在另外的实施方案中，将至少一种5-LO抑制剂和至少一种另外的治疗剂施用于受试者以治疗骨髓增生性疾病。 根据本发明的实施方案提供了抑制白血病干细胞的方法，其包括使白血病干细胞与有效量的花生四烯酸5-脂氧合酶抑制剂接触。

    SYSTEMS AND METHODS FOR STATISTICAL GENOMIC DNA BASED ANALYSIS AND EVALUATION
    3.
    发明申请
    SYSTEMS AND METHODS FOR STATISTICAL GENOMIC DNA BASED ANALYSIS AND EVALUATION 审中-公开
    用于统计基因组DNA分析和评估的系统和方法

    公开(公告)号：WO2007089583A9

    公开(公告)日：2008-04-24

    申请号：PCT/US2007002167

    申请日：2007-01-26

    Applicant: JACKSON LAB ,  AKILESH SHREERAM ,  MILLS KEVIN D ,  ROOPENIAN DERRY CHARLES ,  SHAFFER DANIEL J

    Inventor： AKILESH SHREERAM ,  MILLS KEVIN D ,  ROOPENIAN DERRY CHARLES ,  SHAFFER DANIEL J

    IPC: G06F19/18 ,  G06F19/20 ,  G06F19/24

    CPC classification number: G06F19/20 ,  G06F19/18 ,  G06F19/24

    Abstract: A flexible seal ring (131) includes a first sealing face (150) and a rear face (156) is disposed opposite the front sealing face, the rear face (156) is axially offset relative to the front sealing face. An upper face (154) disposed between the first sealing face (150) and the rear face (156), the upper face (154) extending from the rear face (156) towards the first sealing face (150) such that an interior angle between the upper face (154) and the rear face (156) is greater than 110 degrees. Another flexible seal ring includes a first front sealing face (150), a rear face (156), at least one downwardly disposed upper face (154) disposed between the front sealing face and the rear face, at least one downwardly disposed lower face (158) and a second front sealing face (160) disposed between the downwardly disposed lower face and the first front sealing face. A cartridge seal includes a flexible seal ring (131) and an upper retaining ring (133).

    Abstract translation: 柔性密封环（131）包括第一密封面（150），并且后表面（156）设置成与前密封面相对，后表面（156）相对于前密封面轴向偏移。 设置在第一密封面（150）和后表面（156）之间的上表面（154），上表面（154）从后表面（156）朝向第一密封面（150）延伸，使得内角 在上表面（154）和后表面（156）之间的距离大于110度。 另一个柔性密封环包括第一前密封面（150），后表面（156），设置在前密封面和后表面之间的至少一个向下设置的上表面（154），至少一个向下布置的下表面 158）和设置在向下布置的下表面和第一前密封面之间的第二前密封面（160）。 盒密封件包括柔性密封环（131）和上保持环（133）。

    FCRN-BASED THERAPEUTICS FOR THE TREATMENT OF AUTO-IMMUNE DISORDERS
    4.
    发明申请
    FCRN-BASED THERAPEUTICS FOR THE TREATMENT OF AUTO-IMMUNE DISORDERS 审中-公开
    用于治疗自身免疫性疾病的基于FCRN的治疗方法

    公开(公告)号：WO0243658A9

    公开(公告)日：2002-10-03

    申请号：PCT/US0144166

    申请日：2001-11-06

    Applicant: JACKSON LAB

    Inventor： ROOPENIAN DERRY

    IPC: C07K14/735 ,  C12N15/85 ,  A01K67/00 ,  C12N5/00 ,  C12Q1/00 ,  C12Q1/68 ,  C12Q1/70 ,  G01N33/00 ,  G01N33/53 ,  A01K67/27

    CPC classification number: C12N15/8509 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0325 ,  A61K2039/505 ,  C07K14/70535

    Abstract: Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene, wherein said homozygous disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a subtantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. Also disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene, wherein said homozygous disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse which is unable to absorb maternal IgG in the prenatal or neonatal stage of development. Methods of using the transgenic knockout mouse, and cells derived therefrom, are also disclosed.

    Abstract translation: 公开了一种转基因敲除小鼠，其基因组包含其内源FcRn基因中的纯合破坏，其中所述纯合破坏阻止功能性FcRn蛋白的表达，导致转基因敲除小鼠，其中外源施用的IgG1表现出较短的半衰期， 与外源性IgG1在野生型小鼠中的半衰期相比。 还公开了一种转基因敲除小鼠，其基因组包含其内源性FcRn基因中的纯合破坏，其中所述纯合破坏阻止功能性FcRn蛋白的表达，导致在产前或新生儿中不能吸收母体IgG的转基因敲除小鼠 发展阶段 还公开了使用转基因敲除小鼠的方法及其衍生的细胞。

    METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES
    7.
    发明申请
    METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES 审中-公开
    有关血液恶性肿瘤的方法和组合物

    公开(公告)号：WO2010124283A4

    公开(公告)日：2011-04-21

    申请号：PCT/US2010032416

    申请日：2010-04-26

    Applicant: JACKSON LAB ,  LI SHAOGUANG

    Inventor： LI SHAOGUANG

    IPC: A61K31/38 ,  A61K31/415 ,  A61K31/65 ,  A61P19/08 ,  A61P35/00

    CPC classification number: A61K31/38 ,  A61K31/415 ,  A61K31/65 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5- lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the present invention. In some embodiments, two or more 5-LO inhibitors are administered to a subject to treat a myeloproliferative disorder. In further embodiments, at least one 5-LO inhibitor and at least one additional therapeutic agent are administered to a subject to treat a myeloproliferative disorder. Methods of inhibiting leukemia stem cells are provided according to embodiments of the present invention which include contacting leukemia stem cells with an effective amount of an arachidonate 5-lipoxygenase inhibitor.

    Abstract translation: 根据本发明的实施方案，提供了治疗患有骨髓增生性疾病或具有患骨髓增生性疾病风险的受试者的方法，其包括向受试者施用治疗有效量的花生四烯酸5-脂氧合酶（5-LO）抑制剂。 根据本发明的实施方案施用治疗剂的组合。 在一些实施方案中，向受试者施用两种或更多种5-LO抑制剂以治疗骨髓增生性病症。 在进一步的实施方案中，将至少一种5-LO抑制剂和至少一种另外的治疗剂施用于受试者以治疗骨髓增生性病症。 根据本发明的实施方案提供了抑制白血病干细胞的方法，其包括使白血病干细胞与有效量的花生四烯酸5-脂氧合酶抑制剂接触。

Patent Agency Ranking